Technical Analysis for VRTX - Vertex Pharmaceuticals Incorporated

Grade Last Price % Change Price Change
grade B 221.11 0.69% 1.51
VRTX closed up 0.69 percent on Tuesday, December 10, 2019, on 49 percent of normal volume.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Very Strong Up Up Flat
See historical VRTX trend table...

Date Alert Name Type % Chg
1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Slingshot Bullish Bullish Swing Setup 0.00%
Overbought Stochastic Strength 0.00%
Slingshot Bullish Bullish Swing Setup 0.69%
New 52 Week High Strength 0.69%
Outside Day Range Expansion 0.69%
Overbought Stochastic Strength 0.69%
Slingshot Bullish Bullish Swing Setup -0.96%
New 52 Week High Strength -0.96%
Older signals for VRTX ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. Its products include telaprevir for the treatment of adults with genotype 1 hepatitis C virus (HCV) infection, which is marketed in the United States and Canada under the INCIVEK brand name; and ivacaftor for the treatment of cystic fibrosis that is marketed in the United States, Canada, and Europe under the KALYDECO brand name. The company, through its collaboration agreement with Janssen Pharmaceutica, N.V., also markets telaprevir in Europe and other countries in Janssen's territories under the INCIVO brand name, as well as in Japan under TELAVIC brand name. It is also developing drug candidates for the treatment of cystic fibrosis, including VX-809, which is in Phase III clinical trial and VX-661 that is in Phase II clinical trial; and drug candidates for the treatment of HCV infection, such as VX-135 (ALS-2200), which is in Phase II clinical trial and VX-222 that is in Phase II clinical trial. In addition, the company develops VX-509, which is in Phase II clinical trial for the treatment of autoimmune disease; and VX-787 that is in Phase II clinical trial for the treatment of influenza. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Cambridge, Massachusetts.
Chemistry Chemical Compounds Organic Compounds Infection Influenza Cystic Fibrosis Serious Diseases Autoimmune Disease Cyclopropanes Breakthrough Therapy Hepatitis C Virus Organofluorides Treatment Of Cystic Fibrosis HCV Infection

Is VRTX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 225.66
52 Week Low 151.8
Average Volume 1,239,394
200-Day Moving Average 182.35
50-Day Moving Average 197.71
20-Day Moving Average 216.83
10-Day Moving Average 221.37
Average True Range 4.17
ADX 54.33
+DI 25.23
-DI 10.28
Chandelier Exit (Long, 3 ATRs ) 213.14
Chandelier Exit (Short, 3 ATRs ) 209.23
Upper Bollinger Band 229.28
Lower Bollinger Band 204.37
Percent B (%b) 0.67
BandWidth 11.48
MACD Line 6.82
MACD Signal Line 7.68
MACD Histogram -0.8523
Fundamentals Value
Market Cap 55.75 Billion
Num Shares 252 Million
EPS 1.04
Price-to-Earnings (P/E) Ratio 212.61
Price-to-Sales 17.01
Price-to-Book 21.57
PEG Ratio 1.22
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 226.17
Resistance 3 (R3) 225.86 223.86 225.32
Resistance 2 (R2) 223.86 222.58 224.02 225.04
Resistance 1 (R1) 222.49 221.78 223.18 222.80 224.76
Pivot Point 220.49 220.49 220.84 220.65 220.49
Support 1 (S1) 219.12 219.21 219.81 219.43 217.46
Support 2 (S2) 217.12 218.41 217.28 217.18
Support 3 (S3) 215.75 217.12 216.90
Support 4 (S4) 216.06